Get the Stockscreener App
8.69
2.69%
-0.24
After Hours:
8.84
0.15
+1.73%
Immatics N V stock is traded at $8.69, with a volume of 338.05K.
It is down -2.69% in the last 24 hours and down -4.30% over the past month.
Immatics NV is a clinical-stage biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.
See More
Previous Close:
$8.93
Open:
$8.86
24h Volume:
338.05K
Relative Volume:
0.74
Market Cap:
$1.19B
Revenue:
$43.34M
Net Income/Loss:
$-247.99M
P/E Ratio:
-4.4027
EPS:
-1.9738
Net Cash Flow:
$-224.28M
1W Performance:
-6.05%
1M Performance:
-4.30%
6M Performance:
-15.05%
1Y Performance:
+52.72%
1-Day Range:
$8.56
$8.905
1-Week Range:
$8.40
$9.31
52-Week Range:
$5.05
$12.41
Immatics N V Stock (IMTX) Company Profile
Compare IMTX vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMTX
Immatics N V
|
8.69 | 1.17B | 43.34M | -247.99M | -224.28M | -1.9738 |
VRTX
Vertex Pharmaceuticals Inc
|
547.59 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
828.50 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,011.11 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
138.89 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
211.58 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Immatics N V Stock (IMTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-16-26 | Resumed | Jefferies | Buy |
| Sep-18-25 | Initiated | Guggenheim | Buy |
| May-28-25 | Initiated | Deutsche Bank | Buy |
| Oct-07-24 | Initiated | Piper Sandler | Overweight |
| Nov-02-23 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-31-23 | Initiated | Mizuho | Buy |
| Mar-24-23 | Initiated | Bryan Garnier | Buy |
| Nov-20-20 | Initiated | BofA Securities | Buy |
| Sep-22-20 | Initiated | Goldman | Buy |
| Jul-27-20 | Initiated | SVB Leerink | Outperform |
| Jul-24-20 | Initiated | Jefferies | Buy |
View All
Immatics N V Stock (IMTX) Latest News
Immatics N.V. (NASDAQ:IMTX) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
James Nelson Pepin Net Worth (2026) - GuruFocus
Immatics (NASDAQ:IMTX) Shares Down 8%Should You Sell? - MarketBeat
symbol__ Stock Quote Price and Forecast - CNN
Immatics Announces Second Quarter 2026 Financial Results and Business Update - Sahm
Immatics (IMTX) awards counsel Nelson 225K share package - Stock Titan
Immatics Releases Q2 2026 Financial Results - AlphaStreet
Immatics Q2 revenue rises to $10.4 million - grafa.com
Immatics earnings on deck as analysts eye revenue trajectory - Investing.com
Immatics Q2 Results: EPS misses estimate, sales up 93% YoY - scanx.trade
IMTX Looks 176.9% Overvalued on GF Value™ - GuruFocus
Immatics (NASDAQ:IMTX) Issues Earnings Results - MarketBeat
Immatics (IMTX) Slides 2.01% as Shares Approach Key $8.79 Support LevelQuality Factor - Vinanet
Immatics Posts Interim Q2 2026 Results and Updates Investor Materials - TipRanks
Immatics' Q2 Net Loss Narrows as Revenue Rises - marketscreener.com
Earnings Flash (IMTX) Immatics Posts Q2 Revenue 9.1M Euros, vs. FactSet Est of 10.4M Euros - marketscreener.com
Earnings Flash (IMTX) Immatics Posts Q2 Net Loss 0.46 Euros a Share, vs. FactSet Est of 0.45 Euros Loss - marketscreener.com
Immatics reports Q2 EPS (46c), consensus (48c) - TipRanks
Immatics: Q2 Earnings Snapshot - marketscreener.com
Immatics (NASDAQ: IMTX) posts €120m loss funding Phase 3 melanoma push - Stock Titan
Immatics N.V. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Press Release: Immatics Announces Second Quarter 2026 Financial Results and Business Update - Moomoo
IMTX Q1 2026 Earnings: Wider-than-Expected Loss Reflects Continued Pipeline InvestmentEPS Surprise History - vinanet.vn
Immatics (IMTX) Q1 2026 Earnings: Wider-than-Expected Loss Reflects Continued Preclinical and Clinical InvestmentConsensus Beat Rate - dars.gov.et
Immatics (IMTX): Baker Bros. group reports 9.5M-share, 7% ownership stake - Stock Titan
Immatics NV (IMTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Immatics N.V. expected to post a loss of 43 cents a shareEarnings Preview - TradingView
Immatics N.V. (IMTX) Stock Analysis: Unveiling An 89.67% Potential Upside For Investors - DirectorsTalk Interviews
IMTX Q1 2026 Earnings: Wider-than-Expected Loss Reflects R&D-Driven BurnDividend Cut Risk - vinanet.vn
How Immatics N.v. (IMTX) Affects Rotational Strategy Timing - Stock Traders Daily
Immatics (IMTX): Will Anzu-cel Take The PRAME Crown In Advanced Melanoma? - RTTNews
Immatics (IMTX) Expected to Release Quarterly Earnings on Wednesday - MarketBeat
Immatics (IMTX) Slips 5.9% to $8.66 as Biotech Selling Pressure IntensifiesIron Condor Alert - Vinanet
Immatics N.V. (IMTX) Stock Analysis: Exploring a 105% Upside Potential in the Biotech Sector - DirectorsTalk Interviews
IMTX|Immatics NV|Price:9.425|Chg%:-0.165 - TradingKey
Immatics (NASDAQ:IMTX) Sees Strong Trading VolumeHere's What Happened - MarketBeat
Immatics Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Immatics N.V. (IMTX) Q1 2026 Earnings: Wider-than-Expected Loss Amid Continued Clinical ProgressFinancial Data - dars.gov.et
Immatics NV (IMTX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Immatics N.V. (NASDAQ:IMTX) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Immatics NV (IMTX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Immatics Market Sentiment - Benzinga
Immatics NV (IMTX) Cash Flow - TradingKey
Immatics N.V. Revenue Breakdown – NASDAQ:IMTX - TradingView
IMTX|Immatics NV|Price:9.080|Chg%:-0.210 - TradingKey
Immatics NV (IMTX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Immatics NV (IMTX) Income Statement - TradingKey
Immatics N.V. (IMTX) Stock Analysis: A Deep Dive Into Its 103% Potential Upside - DirectorsTalk Interviews
Immatics NV (IMTX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Immatics NV : Leerink Partners Assumes Covera - Moomoo
Immatics stock trades steady as pipeline and cash position frame biotech outlook - Ad-hoc-news.de
Immatics N V Stock (IMTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.00%
3.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):